|
Variables
|
Overall survival
|
Progression-free survival
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
A (univariate)
|
|
Gender
|
|
Male
|
1.50 (0.56–3.96)
|
0.414
|
0.97 (0.42–2.25)
|
0.954
|
|
Female
|
1
| |
1
| |
|
Age (years)
|
|
≥ 60
|
0.47 (0.21–1.05)
|
0.069
|
0.49 (0.23–1.04)
|
0.065
|
|
< 60
|
1
| |
1
| |
|
Smoking status
|
|
Ever smokers
|
1.08 (0.46–2.56)
|
0.852
|
0.81 (0.37–1.73)
|
0.581
|
|
Never smokers
|
1
| |
1
| |
|
cStage
|
|
IV
|
1.22 (0.58–2.56)
|
0.597
|
1.15 (0.58–2.27)
|
0.681
|
|
III
|
1
| |
1
| |
|
Tumor differentiation
|
|
Poor
|
1.30 (0.58–2.91)
|
0.52
|
1.29 (0.60–2.75)
|
0.512
|
|
Well/moderate
|
1
| |
1
| |
|
Performance status
|
|
1–2
|
1.72 (0.72–4.06)
|
0.215
|
1.30 (0.63–2.68)
|
0.471
|
|
0
|
1
| |
1
| |
|
B
|
1.29 (0.91–2.03)
|
0.328
|
1.17 (0.96–1.82)
|
0.532
|
|
NK
|
0.97 (0.57–1.82)
|
0.165
|
0.92 (0.62–1.56)
|
0.181
|
|
NKT
|
1.19 (0.73–1.65)
|
0.720
|
1.21 (0.86–1.76)
|
0.824
|
|
γδT
|
0.65 (0.35–1.36)
|
0.611
|
0.78 (0.43–1.44)
|
0.955
|
|
CD8+CD28+
|
1.01 (0.94–1.10)
|
0.749
|
0.99 (0.93–1.07)
|
0.902
|
|
CD8+CD28−
|
2.01 (1.16–4.05)
|
0.039
|
2.12 (1.07–4.36)
|
0.023
|
|
CD28+/CD28−
|
0.96 (0.68–1.37)
|
0.863
|
0.87 (0.61–1.22)
|
0.414
|
|
CD4+CD25hi
|
1.17 (0.68–2.04)
|
0.570
|
1.28 (0.78–2.10)
|
0.331
|
|
B (multivariate)
|
|
Age (years)
|
0.47 (0.21–1.05)
|
0.064
|
0.48 (0.22–1.02)
|
0.057
|
|
CD8+CD28−
|
1.41 (1.17–3.06)
|
0.035
|
2.01 (1.06–3.85)
|
0.029
|
- P-values for multivariate analyses are adjusted. The HR and 95% CI were reported for 1 SD increase for immune cells
